Severe oropharyngeal candidiasis in an anemic pregnant woman: A case report.

Hormonal fluctuations during pregnancy increase susceptibility to infections, typically presenting as vulvovaginal candidiasis, but rarely as oropharyngeal candidiasis. We report a rare case of a woman being pregnant for 27 + 1 weeks with twins with oropharyngeal candidiasis, likely attributed to nutritional anemia and adverse reactions of amoxicillin. Following a thorough literature review and evaluation of medication safety during pregnancy regarding route, dosage, and gestational stage, we treated the patient with fluconazole and piperacillin-tazobactam.

Application of nirmatrelvir/ritonavir for the treatment of severe COVID-19 in a 3-year-old child.

Introduction: Nirmatrelvir/ritonavir (Paxlovid) is an effective antiviral drug for treating coronavirus disease 2019 (COVID-19) in adults. However, Paxlovid treatment of children, especially those who are under 12 years and with severe underlying diseases, is rare.

Case Report: A three-year-old COVID-19 patient (weighing 14.

Enzyme replacement therapy for infantile-onset Pompe disease.

Background: Infantile-onset Pompe disease is a rare and progressive autosomal-recessive disorder caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). Current treatment involves enzyme replacement therapy (with recombinant human alglucosidase alfa) and symptomatic therapies (e.g.

A prospective study of the use of antibiotics in the Emergency Department of a Chinese University Hospital.

Background: Antibiotics are one of the most widely misused group of medicines. The aim of this study was to investigate the use of antibiotics in one of the paediatric emergency departments in China.

Methods: We performed a prospective, cross-sectional study of antibiotic use in the paediatric emergency room of West China Second University Hospital.

20% subcutaneous immunoglobulin for patients with primary immunodeficiency diseases: A systematic review.

Background: Primary immunodeficiency diseases (PID) are a group of rare disorders that patients do not have normal function of the immune system. Subcutaneous immunoglobulin 20% (SCIG-20%) was a candidate when considering replacement therapy with immunoglobulin in PID, but the evidence was not clear. To understand and interpret the available evidence, we conducted a systematic review to assess the efficacy and safety of SCIG-20% for patients with PID.